Carl W. Dieffenbach
Uniformed Services University of the Health Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carl W. Dieffenbach.
Journal of Vascular Surgery | 1991
John B. Sharefkin; Scott L. Diamond; Suzanne G. Eskin; Larry V. McIntire; Carl W. Dieffenbach
Endothelin-1, a 21-amino acid peptide secreted by endothelial cells, has constrictor and mitogenic activity for vascular smooth muscle cells, and its mitogenic activity is synergistic with that of platelet-derived growth factor. Endothelial cell-derived endothelin-1 might therefore contribute to intimal hyperplasia in reendothelialized segments of vascular grafts or of endarterectomy and angioplasty sites. Because intimal hyperplasia occurs most often at sites with disordered flow patterns and lower fluid shear stress, we tested the effects of static culture versus high laminar shear stress (25 dyne/cm2) on endothelin-1 precursor (preproendothelin) gene mRNA transcript levels and endothelin-1 peptide release in cultured human endothelial cells. Primary cultures of human umbilical vein endothelial cells were subjected to controlled levels of shear stress in parallel plate flow chambers for 24 hours. To detect preproendothelin mRNA we applied a linked reverse transcriptase-polymerase chain reaction (RT/PCR) to RNA extracted from cultures. Southern blots of RT/PCR reaction products were hybridized with radioactive phosphorous (32P) labeled probes for the amplified preproendothelin complementary deoxyribonucleic acid (cDNA). Detection by RT/PCR of mRNA for glyceraldehyde 3-phosphate dehydrogenase was used to measure a constitutively expressed control signal. Endothelin-1 release into culture medium was measured by radioimmunoassay. Application of 25 dyne/cm2 of shear stress for 24 hours sharply reduced endothelial cell levels of precursor preproendothelin mRNA.(ABSTRACT TRUNCATED AT 250 WORDS)
Pathobiology | 1991
Monte S. Meltzer; Lisa M. Baca; Jim A. Turpin; Chester Kalter; Carl W. Dieffenbach; Robert M. Friedman; Howard E. Gendelman
Monocytes treated with interferon-alpha (IFN-alpha) at virus challenge show no evidence of human immunodeficiency virus (HIV) infection: no p24 antigen or reverse transcriptase (RT) activity, no viral mRNA and no proviral DNA. Levels of p24 antigen and RT activity in monocytes infected with HIV 1-3 weeks before IFN-alpha treatment gradually decrease to baseline. HIV-induced cytopathic changes are markedly reduced, as are levels of HIV mRNA: the frequency of productively infected cells is less than or equal to 1%. But, levels of proviral DNA in the IFN-alpha-treated and control HIV-infected cells are indistinguishable, and remain so through 3 weeks. Large quantities of proviral DNA in IFN-alpha-treated cells with little active transcription suggest true microbiological latency. The major potential source for IFN-alpha in HIV-infected patients is the macrophage. With any of 15 virus isolates, tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, IFN-omega or IFN-beta are not detected nor the mRNA expressed in HIV-infected or uninfected monocytes. Both uninfected and HIV-infected monocytes produce high levels of these cytokines after treatment with synthetic double-stranded RNA (poly-I:C). Uninfected monocytes also produce high levels of IFN-alpha after treatment with Poly-I:C, Newcastle disease virus or herpes simplex virus. In marked contrast, HIV-infected monocytes express no IFN-alpha activity or mRNA before or after treatment with any of these agents. The markedly diminished capacity of HIV-infected monocyte to produce IFN-alpha reflects a specific transcriptional block and may be an adaptive mechanism of virus to alter basic microbicidal functions of this cell.(ABSTRACT TRUNCATED AT 250 WORDS)
PCR primer: a laboratory manual. | 2003
Carl W. Dieffenbach; Gabriela S. Dveksler
Nucleic Acids Research | 1990
Todd Lowe; John B. Sharefkin; Shi Qi Yang; Carl W. Dieffenbach
Journal of Cellular Physiology | 1990
Scott L. Diamond; John B. Sharefkin; Carl W. Dieffenbach; K. Frasier-Scott; Larry V. McIntire; Suzanne G. Eskin
Journal of Immunology | 1991
Kalter Dc; Nakamura M; Jim A. Turpin; Lisa M. Baca; David L. Hoover; Carl W. Dieffenbach; P Ralph; Howard E. Gendelman; Monte S. Meltzer
Journal of Immunology | 1990
Howard E. Gendelman; Lisa M. Baca; Jim A. Turpin; Kalter Dc; Brian D. Hansen; Jan M. Orenstein; Carl W. Dieffenbach; Robert M. Friedman; Monte S. Meltzer
FEBS Journal | 1985
David Krause; Robert H. Silverman; Helmut Jacobsen; Sharon A. Leisy; Carl W. Dieffenbach; Robert M. Friedman
Microbial Pathogenesis | 1991
Jeannine A. Majde; Ray K. Brown; Michael W. Jones; Carl W. Dieffenbach; Niranjan Maitra; James M. Krueger; A. B. Cady; Curt W. Smitka; Hunein F. Maassab
Journal of Biological Chemistry | 1989
Carl W. Dieffenbach; D N SenGupta; David Krause; D Sawzak; Robert H. Silverman